EUROPE IN-VITRO FERTILIZATION MARKET FORECAST 2017-2026
KEY FINDINGS
The Europe in-vitro fertilization market is hailed as a pioneering market at the global scene. The market accounted for a revenue of $ 4469 million in 2016. On account of an expected CAGR 9.04%, the market is anticipated to generate $ 10605 million by the end of the forecast period of 2017-2026,
MARKET INSIGHTS
Europe in vitro fertilization market extends its applications in hospitals & research laboratories, cryobanks, and fertility & surgical centers. The regional market is experiencing a significant rise due to factors like declining fertility rate, rising government support for the adoption of in vitro fertilization techniques and increasing success rates of its IVF treatments. The market segments for the Europe in-vitro fertilization market are classified on the basis of procedures, products, and end-users. The rest of Europe market captured the biggest revenue share in the year 2016. However, it is the German market that is slated to exhibit the highest CAGR growth for this region. The success rate of IVF is at 40% for this market.
COMPETITIVE INSIGHTS
Copper Surgical Inc, Thermo Fisher Scientific Inc, Ivftech Aps, the Baker Company Inc, Ferring Pharmaceuticals, Auxogyn, Vitrolife Ab, Cook Medical Inc, Genea, Halotech DNA, Andrology Solutions, Esco Micro Pte. Ltd, Irvine Scientific (Subsidiary of Nippon Mining Holdings), Ovascience, and Merck Serono are some of the established players in the IVF market.
The Europe in-vitro fertilization market is hailed as a pioneering market at the global scene. The market accounted for a revenue of $ 4469 million in 2016. On account of an expected CAGR 9.04%, the market is anticipated to generate $ 10605 million by the end of the forecast period of 2017-2026,
MARKET INSIGHTS
Europe in vitro fertilization market extends its applications in hospitals & research laboratories, cryobanks, and fertility & surgical centers. The regional market is experiencing a significant rise due to factors like declining fertility rate, rising government support for the adoption of in vitro fertilization techniques and increasing success rates of its IVF treatments. The market segments for the Europe in-vitro fertilization market are classified on the basis of procedures, products, and end-users. The rest of Europe market captured the biggest revenue share in the year 2016. However, it is the German market that is slated to exhibit the highest CAGR growth for this region. The success rate of IVF is at 40% for this market.
COMPETITIVE INSIGHTS
Copper Surgical Inc, Thermo Fisher Scientific Inc, Ivftech Aps, the Baker Company Inc, Ferring Pharmaceuticals, Auxogyn, Vitrolife Ab, Cook Medical Inc, Genea, Halotech DNA, Andrology Solutions, Esco Micro Pte. Ltd, Irvine Scientific (Subsidiary of Nippon Mining Holdings), Ovascience, and Merck Serono are some of the established players in the IVF market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE DOMINATES THE EUROPE IVF MARKET
3.2.2. INSURANCE COVERAGE FOR IVF
3.2.3. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. COUNTRY OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. UNITED KINGDOM
8.2. FRANCE
8.3. GERMANY
8.4. SPAIN
8.5. REST OF EUROPE
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE DOMINATES THE EUROPE IVF MARKET
3.2.2. INSURANCE COVERAGE FOR IVF
3.2.3. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. COUNTRY OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. UNITED KINGDOM
8.2. FRANCE
8.3. GERMANY
8.4. SPAIN
8.5. REST OF EUROPE
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
LIST OF TABLES
Table 1 EUROPE IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 EUROPE IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 EUROPE IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 EUROPE IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 EUROPE IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 EUROPE IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 1 EUROPE IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 EUROPE IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 EUROPE IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 EUROPE IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 EUROPE IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 EUROPE IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
LIST OF FIGURES
Figure 1 EUROPE IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 3 EVOLUTION OF IVF MARKET
Figure 4 EUROPE REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 EUROPE EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 EUROPE INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 EUROPE PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 EUROPE FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 EUROPE OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 EUROPE FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 EUROPE HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 EUROPE CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR EUROPE IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR EUROPE IVF MARKET BY END-USER - 2016
Figure 15 UNITED KINGDOM IVF MARKET 2017-2026 ($ MILLION)
Figure 16 FRANCE IVF MARKET 2017-2026 ($ MILLION)
Figure 17 GERMANY IVF MARKET 2017-2026($MILLION)
Figure 18 SPAIN IVF MARKET 2017-2026 ($ MILLION)
Figure 19 REST OF EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 20 EUROPE IVF MARKET SHARE OF MAJOR COMPANIES – 2016
Figure 1 EUROPE IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 3 EVOLUTION OF IVF MARKET
Figure 4 EUROPE REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 EUROPE EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 EUROPE INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 EUROPE PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 EUROPE FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 EUROPE OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 EUROPE FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 EUROPE HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 EUROPE CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR EUROPE IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR EUROPE IVF MARKET BY END-USER - 2016
Figure 15 UNITED KINGDOM IVF MARKET 2017-2026 ($ MILLION)
Figure 16 FRANCE IVF MARKET 2017-2026 ($ MILLION)
Figure 17 GERMANY IVF MARKET 2017-2026($MILLION)
Figure 18 SPAIN IVF MARKET 2017-2026 ($ MILLION)
Figure 19 REST OF EUROPE IVF MARKET 2017-2026 ($ MILLION)
Figure 20 EUROPE IVF MARKET SHARE OF MAJOR COMPANIES – 2016
